华特达因：关于子公司达因药业获得药品注册证书的公告

Core Viewpoint - The company announced that its subsidiary, Dain Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Clonidine Hydrochloride Extended-Release Tablets, specifically for the treatment of ADHD in children aged 6-17 years [2] Group 1 - The approved product is Clonidine Hydrochloride Extended-Release Tablets with a specification of 0.1mg [2] - The approval number for the product is Guoyao Zhunzi H20256411, and it is valid until December 29, 2030 [2]